ACB FINAL DEADLINE TODAY ROSEN, A TOP RANKED LAW FIRM, Reminds Aurora Cannabis Inc. Investors of Important Tuesday Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $1MM to Contact the Firm – ACB

Nachrichtenquelle: Business Wire (engl.)
21.01.2020, 15:42  |  350   |   |   

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between October 23, 2018 and January 6, 2020, inclusive (the “Class Period”) of the important January 21, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1724.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Aurora’s revenue would decline in its first quarter of fiscal 2020 ended September 30, 2019; (2) the Company would halt construction on its Aurora Nordic 2 and Aurora Sun facilities; (3) Aurora had exaggerated and/or overestimated the demand for and potential market for its consumer use cannabis products; (4) as a result, Aurora was overproducing consumer use cannabis products, leading to construction and production inefficiencies as well as the oversupply of products to its non-warehouse and warehouse customers; (5) Aurora was utilizing an unpermitted, proprietary form of treatment in the production process of its medical Cannabis geared to obtain a longer shelf life of the products, which violates German law mandating that companies receive special permission to distribute medical products exposed to ionizing irradiation; and (6) due to the foregoing, defendants’ statements about Aurora’s receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 21, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1724.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.

Aurora Cannabis Aktie jetzt für 4€ handeln - auf Smartbroker.de



Diesen Artikel teilen

Diskussion: Aurora Cannabis einfach TOP !!!

Diskussion: Aurora Cannabis wandert ins Tief – Diese 3 Faktoren zeigen, wie es mit der Aktie weiter geht
Wertpapier

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
CannabisTwitterFIRVIIFF


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel